Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis

被引:19
|
作者
Devlen, Jennifer [1 ]
Beusterien, Kathleen [2 ]
Yen, Linnette [3 ]
Ahmed, Awais
Cheifetz, Adam S. [4 ]
Moss, Alan C. [5 ]
机构
[1] ICON Plc Co, Patient Reported Outcomes, Oxford Outcomes, Bethesda, MD USA
[2] Hlth LLC, Outcomes Res Stategies, Washington, DC USA
[3] Shire, Global Hlth Econ & Outcomes Res, Global Med Affairs, Wayne, NJ USA
[4] IBD Ctr, Boston, MA USA
[5] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA 02215 USA
来源
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2014年 / 20卷 / 03期
关键词
5-AMINOSALICYLIC ACID THERAPY; QUIESCENT ULCERATIVE-COLITIS; MEDICATION NONADHERENCE; OF-LIFE; EXPERIENCES; PREDICTORS; MANAGEMENT; SYMPTOMS; OUTCOMES; IMPACT;
D O I
10.18553/jmcp.2014.20.3.309
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
(BACKGROUND: The causes for nonadherence to mesalamine in patients with inflammatory bowel disease (IBD) have been characterized using mostly indirect methods. Patient-reported barriers are lacking in this population. OBJECTIVE To identify patient-reported barriers to mesalamine adherence through direct interviews. METHODS Focus groups and one-on-one interviews were undertaken in adult patients with Transcripts from the focus groups and interviews were analyzed to identify themes and links between these themes, assisted by qualitative data software MaxCDA. RESULTS: 027 patients participating, 21 (78%) had ulcerative colitis, and 6(22%) had Crohn's disease. Their self-reported adherence ranged from complete adherence (n= 3) to intermittent nonadherence (n=24). Patients frequently indicated that they were resistant to taking medications for their condition. The barriers to adherence that emerged from interviews could be categorized under a number of themes: competing priorities, social stigma, refill inconvenience, costs, efficacy values, side effects, and pill characteristics. Efficacy values reported to influence adherence included doubts about efficacy, consequences of missed doses, and doubts about need for maintenance medication. Fill characteristics reported as barriers included pill size and 011 frequency. [spite use of electronic prescribing, obtaining refills was reported as an obstacle to adherence in this cohort. Decanting of pills to multiple containers to increase accessibility was also reported. CONCLUSIONS Patients with both colitis and Dohn's disease report a number of common barriers to mesalamine adherence. Factors in medication-taking behavior and beliefs were reported in this study that may have implications for strategies to improve adherence by health care providers.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 50 条
  • [1] Factors Influencing Adherence to Mesalamine in Patients with Inflammatory Bowel Disease: A Patient-Reported Qualitative Analysis
    Moss, Alan
    Beusterien, Kathy
    Ahmed, Awais
    Cheifetz, Adam
    Devlen, Jennifer
    Yen, Linette
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S442 - S442
  • [2] Clinician Adherence to Inflammatory Bowel Disease Guidelines: Results of a Qualitative Study of Barriers and Enablers
    Kanazaki, Ria
    Smith, Ben
    Girgis, Afaf
    Connor, Susan J.
    CROHNS & COLITIS 360, 2023, 5 (03)
  • [3] Mesalamine prevents dysplasia in patients with inflammatory bowel disease
    Aharoni, I
    Kornbluth, A.
    Li, J.
    Kodsi, R.
    Tenner, S.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 655 - 655
  • [4] Mesalamine prevents dysplasia in patients with inflammatory bowel disease
    Aharoni, I
    Safdar, S
    Kornbluth, A
    Li, JJ
    Kodsi, R
    Tenner, S
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S314 - S314
  • [5] Barriers to Adherence Among Adolescents with Inflammatory Bowel Disease
    Greenley, Rachel Neff
    Stephens, Mike
    Doughty, Alyssa
    Raboin, Tara
    Kugathasan, Subra
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (01) : 36 - 41
  • [6] Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine
    Margetts, PJ
    Churchill, DN
    Alexopoulou, I
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 32 (02) : 176 - 178
  • [7] Barriers to Oral Medication Adherence for Adolescents with Inflammatory Bowel Disease
    Ingerski, Lisa M.
    Baldassano, Robert N.
    Denson, Lee A.
    Hommel, Kevin A.
    JOURNAL OF PEDIATRIC PSYCHOLOGY, 2010, 35 (06) : 683 - 691
  • [8] A Practical Approach to Identify Non-Adherence to Mesalamine Therapy in Inflammatory Bowel Disease
    Vernia, Filippo
    Scotti, Giorgia Burrelli
    Borghini, Raffaele
    Muselli, Mario
    Necozione, Stefano
    Moretta, Giovanni
    Scurti, Lorenza
    Donato, Giuseppe
    GASTROENTEROLOGY INSIGHTS, 2024, 15 (03) : 754 - 763
  • [9] Obstacles to Medication Adherence for Patients with Inflammatory Bowel Disease: A Qualitative Study in East China
    Xu, Fen
    Xing, Jingjing
    Fan, Mingna
    Zhu, Zhiping
    Chen, Yan
    Hu, Wen
    Zhou, Yunxian
    PATIENT PREFERENCE AND ADHERENCE, 2024, 18 : 2481 - 2494
  • [10] Adherence to medication in inflammatory bowel disease patients
    Bertomoro, Perla
    Vettorato, Maria Grazia
    Mazzocco, Ketti
    Rumiati, Rino
    Sturniolo, Giacomo C.
    D'inca, Renata
    GASTROENTEROLOGY, 2007, 132 (04) : A344 - A344